BRISTOL MYERS SQUIBB CO stock analysis

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheu

Ticker: BMY
Exchange: NYSE
Sector: Health Care
Industry: Pharmaceuticals

Market evidence and data freshness

The public preview recorded BRISTOL MYERS SQUIBB CO at 63.18 USD on 2026-11-05T20:42:50.000Z and marked the quote as delayed. This observation is not a trading signal.

Available price history spans 2026-05-11 through 2026-11-03 across 123 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

Published research mentioning BMY

These are separate dated research reports, not a consensus view or a current signal.

What should I review before buying BRISTOL MYERS SQUIBB CO stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

Inside the full analysis

Valuation
Growth
Financial health
Ownership
Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.